Business Description
PaxMedica Inc. is a clinical-stage drug development company based in Tarrytown, New York, working on treatments for difficult neurological conditions such as autism spectrum disorder, chronic fatigue syndrome, long COVID-19, and a parasitic brain disease called human African trypanosomiasis. The company's primary focus is on a class of treatments that work by blocking purine receptors, with its furthest-along candidate being PAX-101, an intravenous drug currently in Phase 3 trials, alongside an intranasal version and other related compounds in earlier development. PaxMedica also has a research partnership with PolarMar Health to study emodin as a potential autism treatment, with each company holding separate rights to different forms of the product. Founded in 2018 and formerly called Purinix Pharmaceuticals, the company renamed itself PaxMedica in April 2020.